Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-α-peptide prodrugs

Cancer Research

Volumn 60, Issue 3, 2000, Pages 657-665

  Hamstra, Daniel A ^a,b   Pagé, Michel ^c   Maybaum, Jonathan ^a,b   Rehemtulla, Alnawaz ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE A; DECAY ACCELERATING FACTOR; METHOTREXATE; METHOTREXATE ALPHA PEPTIDE; METHOTREXATE ALPHA PHENYLALANINE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG DIFFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CARBOXYPEPTIDASES; CARBOXYPEPTIDASES A; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; METHOTREXATE; PHENYLALANINE; PRODRUGS; TIME FACTORS; TRYPSIN; TUMOR CELLS, CULTURED;

EID: 0033961881     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Krakoff, I. The irrelevant toxicities of anticancer drugs. In: M. Hacker, J. Lazo, and T. Tritton (eds.), Organ Directed Toxicities of Anticancer Drugs, pp. 3-12. Boston: Martinus Nijhoff, 1987.
2. Niculescu-Duvaz, I., Spooner, R., Marais, R., and Springer, C. J. Gene-directed enzyme prodrug therapy. Bioconj. Chem., 9: 4-22, 1998.
3. Tattersall, M. Clinical utility of methotrexate in neoplastic disease. In: F. Siotnak, J. Burchall, W. Ensminger, and J. Montgomery (eds.), Folate Antagonists as Therapeutic Agents, Vol. 2, pp. 166-189. Orlando: Academic Press, 1984.
4. Ensminger, W. Clinical pharmacology of folate analogs. In: F. Siolnak, J. Burchall, W. Ensminger, and J. Montgomery (eds.), Folate Antagonists as Therapeutic Agents, Vol. 2, pp. 133-159. Orlando: Academic Press, 1984.
5. Kuefner, U., Lohrmann, U., Montejano, Y. D., Vitols, K. S., and Huennekens, F. M. Carboxypeptidase-mediated release of methotrexate from methotrexate α-peptides. Biochemistry, 28: 2288-2297, 1989.
6. Oppezzo, O., Ventura, S., Bergman, T., Vendrell, J., Jornvall, H., and Aviles, F. X. Procarboxypeptidase in rat pancreas. Overall characterization and comparison of the activation processes. Eur. J. Biochem., 222: 55-63, 1994.
7. Perron, M. J., and Page, M. Activation of methotrexate-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro. Br. J. Cancer, 73: 281-287, 1996.
8. Smith, G. K., Banks, S., Blumenkopf, T. A., Cory, M., Humphreys, J., Laethem, R. M., Miller, J., Moxham, C. P., Mullin, R., Ray, P. H., Walton, L. M., and Wolfe, L. A., III. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem., 272: 15804-15816, 1997.
9. Nakayama, K. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J., 327: 625-635, 1997.
10. Hamstra, D. A., and Rehemtulla, A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/ Furin family of propeptidases. Hum. Gene Ther., 10: 235-248, 1999.
11. Pei, D., and Weiss, S. J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (Lond.), 375: 244-247, 1995.
12. Rehemtulla, A., and Kaufman, R. J. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood, 79: 2349-2355, 1992.
13. Caras, I. W., Weddell, G. N., Davitz, M. A., Nussenzweig, V., and Martin, D. W., Jr. Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science (Washington DC), 238: 1280-1283, 1987.
14. Sambrook, J., Fritsch, E., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Springs Harbor, NY: Cold Springs Harbor Laboratory, 1989.
15. Hugachi, R. Recombinant PCR. In: M. Innis, D. Gelfand, J. Snisky, and T. White (eds.), PCR Protocols: A Guide to Methods and Applications, pp. 177-183. San Diego: Academic Press, 1990.
16. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-11012, 1990.
17. Perron, M-J., and Page, M. Synthesis of methotrexate prodrugs as an approach for drug targeting. Int. J. Oncol., 5: 907-913, 1994.
18. Rehemtulla, A., Hamilton, C. A., Chinnaiyan, A. M., and Dixit, V. M. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J. Biol. Chem., 272: 25783-25786, 1997.
19. Quinto, C., Quiroga, M., Swain, W. F., Nikovits, W. C., Jr., Standring, D. N., Pictet, R. L., Valenzuela, P., and Rutter, W. J. Rat preprocarboxypeptidase A: cDNA sequence and preliminary characterization of the gene. Proc. Natl. Acad. Sci. USA, 79: 31-35, 1982.
20. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
21. Huber, B. E., Richards, C. A., and Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
22. Fick, J., Barker, F. G., II, Dazin, P., Westphale, E. M., Beyer, E. C., and Israel, M. A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA, 92: 11071-11075, 1995.
23. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.
24. Wygoda, M. R., Wilson, M. R., Davis, M. A., Trosko, J. E., Rehemtulla, A., and Lawrence, T. S. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: the Good Samaritan effect. Cancer Res., 57: 1699-1703, 1997.
25. Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., Trosko, J. E., and Stetson, P. L. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res., 58: 2588-2593, 1998.
26. Hamstra, D. H., Rice, D. J., Pu, A., Oyedijo, D., Ross, B. D., and Rehemtulla, A. Combined radiation and enzyme/prodrug therapy for head and neck cancer in an orthotopic. Anim. Model Rad. Res., in press, 2000.
27. Hock, R. A., and Miller, A. D. Retrovirus-mediated transfer and expression of drug resistance genes in haematopoietic progenitor cells. Nature (Lond.), 320: 275-277, 1986.
28. Williams, D. A., Hsieh, K., DeSilva, A., and Mulligan, R. C. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexale-resistant bone marrow. J. Exp. Med., 166: 210-218, 1987.
29. Li, W. W., Tong, W. P., and Bertino, J. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma lines with intrinsic resistance to methotrexate. Clin. Cancer Res., 10: 631-636, 1995
30. Springer, C. J., Bavetsias, V., Jackman, A. L., Boyle, F. T., Marshall, D., Pedley, R. B., and Bisset, G. M. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Des., 11: 625-636, 1996.
31. Wolfe, L. A., Mullin, R. J., Laethem, R., Blumenkopf, T. A., Cory, M., Miller, J. F., Keith, B. R., Humphreys, J., and Smith, G. K. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconjug. Chem., 10: 38-48, 1999.
32. Marais, R., Spooner, R. A., Stribbling, S. M., Light, Y., Martin, J., and Springer, C. J. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotech., 15: 1373-1377, 1997.
33. Vokes, E. E. Head and neck cancer. In: M. C. Perry (ed.), The Chemotherapy Source Book, Ed. 2, pp. 1083-1101. Baltimore: Williams and Wilkins, 1998.
34. O'Malley, B. W., Jr., Cope, K. A., Johnson, C. S., and Schwartz, M. R. A new immune-competent murine model for oral cancer. Arch. Otolaryngol., 123: 20-24, 1997.
35. Hamstra, D. A., Rice, D. J., Fahmy, S., Ross, B. D., and Rehemtulla, A. Enzyme/ prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum. Gene Ther. 10: 1993-2003, 1999.